Skip to content

Study · In vitro (cells) · 2019

4 results

Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.

Ning Z, Tan B, Chen B, Lau DSA, Wong TM, Sun T, Peng S, Li Z, Lu WW

Macromolecular bioscience8 May 2019Cited by 30 (Europe PMC)

PMID31066995 (opens in a new tab)DOI10.1002/mabi.201900020 (opens in a new tab)PepBankPUB-31066995
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In MC3T3-E1 pre-osteoblasts, abaloparatide significantly promoted cell viability.

    In plain wordsIn cells, abaloparatide increased MC3T3-E1 pre-osteoblast viability.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCell viability
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblasts
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is found that in vitro abaloparatide treatment can promote pre-osteoblast MC3T3-E1 cells' viability, differentiation, and mineralization significantly.
  2. 02LabIn vitro (cells)Efficacy outcome

    In MC3T3-E1 pre-osteoblasts, abaloparatide significantly promoted differentiation.

    In plain wordsIn cells, abaloparatide increased MC3T3-E1 pre-osteoblast differentiation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCell differentiation
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblasts
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is found that in vitro abaloparatide treatment can promote pre-osteoblast MC3T3-E1 cells' viability, differentiation, and mineralization significantly.
  3. 03LabIn vitro (cells)Efficacy outcome

    In MC3T3-E1 pre-osteoblasts, abaloparatide significantly promoted mineralization.

    In plain wordsIn cells, abaloparatide increased MC3T3-E1 pre-osteoblast mineralization.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseMineralization
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblasts
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is found that in vitro abaloparatide treatment can promote pre-osteoblast MC3T3-E1 cells' viability, differentiation, and mineralization significantly.

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Pharmacokinetics

    In laboratory delivery tests, the porous GelMA hydrogel prolonged abaloparatide release to more than 10 days.

    In plain wordsIn lab tests, the porous GelMA hydrogel prolonged abaloparatide release to more than 10 days.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseHydrogel release duration
    Study

    n: not reported in source

    Methacrylated gelatin hydrogel
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    For the drug delivery system, 3D porous structure of the methacrylated gelatin (GelMA) hydrogel is found effective for prolonging the release of abaloparatide (more than 10 days).

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.